Bariatric. Downloaded from at 8:25 CEST on Saturday August 30th in vivo.

Transcript

1 (5 ) Bariatric * 6 :.. bariatric HOMA. (BMI 35) 46 :... HOMA /9±2/09) : BMI.(P<0/000 5/±3/2. :. in vivo.. : - -2 () -3 () -4-5 / -6 : : Hosseinzadeh.MD.PHD@gmail.com :

2 :. Fukuhara. in vivo.... (Cross-sectional) BMI 35 kg/m2 46 Bariatric B C..[ 2].[2]...[3 4] Fukuhara.[5].[5] Factorpre-B-Cell Colony Enhancing PBEF. PBEF (... TNF-α, IL-6 ).[6].. (pro-adipogenic) (pre-adipocyte). (adipocyte).[7]

3 ( 5 ) SPSS. -. (Independent Sample T Test) T. (Pearson Correlation). ±. 0/ (%7/7). 36/0±0/4 45/3 ±5/3 kg/m2.( ) 26±4/8 cm /9±2/09 ng/dl 5/±3/2 ng/dl.( ) (P<0/000).(2 )..(2 ) (r=0/56 P= 0/04) HDL ). ( LDL.(2 ) (r=-0/6 P=0/04). ( 00 ) ( 0/ ) ( 0/ )... ) ( LDL-) (HDL-c) (c. (TG). LDL HDL LDL VLDL DRG RIA. Homeostasis Model Asssessment HOMA (22/5 = HOMA-IR) ELISA.[8] (Human visfatin ELISA kit, AdipoGen Pharmaceuticals, Belmont, Seoul Korea) 30 pg/ml. % 7/5 % 4/3

4 : LDL HDL - 36/0±0/4 ( ) 45/3 ± 5/3 (Kg/m 2 ) 26 ± 4/8 (cm) 84/2 ± 37/7 (mg/dl) 82 ± 07/4 (mg/dl) 05/2 ± 29/4 40/05 ± 0 02 ± 20/7 5/2 ± 8/ 3/6 ± 2/2 (mg/dl) LDL (mg/dl) HDL (mg/dl) (mu/l) HOMA : * ( 33 3) 46: **. ± *** =HDL =LDL. =HOMA LDL HDL -2 0/2 0/33 0/2 (Kg/m 2 ) 0/ 0/56 0/04 (cm) -0/07-0/3-0/45 (mg/dl) -0/7-0/5 -/8 (mg/dl) -0/2-0/4-0/08 (mg/dl) LDL 0/08 0/25-0/06 (mg/dl) HDL -0/3-0/4-0/06 (mg/dl) 0/ 0/ 0/ (µu/dl) 0/00-0/6 0/05 HOMA : *. ** ( 33 3) 46: ***. =HOMA =HDL =LDL ****.(P<0/05) P

5 ( 5 ) [] Fukuhara [5]. in vivo. [5]. [3 2]... TNF- [9] IL-6 α 2. TNF-α IL-6 IL-6.[0] - Chemerin

6 54... :. LDL HDL.[5]. [22 2].[2]. Fukuhara. in. vivo..... [6] [5 4].. BMI. (BMI 35) BMI.[6] ( ).. Moschen Pagano.[8 7] in vivo in vitro Revollo.[5].[9] in vivo HDL-c LDL-c. Jian.[20 4] 3.[5] TG.

7 ( 5 ) Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature 200; 44(6865): Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clinical Chemistry 2004; 50(9):5. 3. Mulhall BP, Ong JP, Younossi ZM. Non alcoholic fatty liver disease: An overview. Journal of gastroenterology and hepatology 2002; 7(): Lafontan M. Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu Rev Pharmacol Toxicol 2005; 45: Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307(5708): Ognjanovic S, Bao S, Yamamoto S, Garibay- Tupas J, Samal B, Bryant-Greenwood G. Genomic organization of the gene coding for human pre-b-cell colony enhancing factor and expression in human fetal membranes. Journal of Molecular Endocrinology 200; 26(2): Aller R, De Luis D, Izaola O, Sagrado MG, Conde R, Velasco M, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Digestive diseases and sciences 2009; 54(8): Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 985; 28(7): Malavazos AE, Ermetici F, Cereda E, Coman C, Locati M, Morricone L, et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor- levels in visceral obesity. Nutrition, Metabolism and Cardiovascular Diseases 2008; 8(8): Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56(4):00.. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clinical endocrinology 200; 72(3): Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Plasma visfatin concentrations and fat depot specific mrna expression in humans. Diabetes 2005; 54(0): Filippatos T, Derdemezis C, Kiortsis D, Tselepis A, Elisaf M. Increased plasma levels of visfatin/pre-b cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. Journal of Endocrinological Investigation 2007; 30(4): Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007; 56(9): Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabetic Medicine 2006; 23(9): Varma V, Yao-Borengasser A, RasouliN, Bodles AM, Phanavanh B, Lee MJ, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. Journal of Clinical Endocrinology & Metabolism 2007; 92(2): Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-b cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Journal of Clinical Endocrinology & Metabolism 2006; 9(8): Moschen AR, Kaser A, Enrich B, MosheimerB, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology 2007; 78(3): Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in [beta] cells as a systemic NAD biosynthetic enzyme. Cell metabolism 2007; 6(5): Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, et al. Association of increased Visfatin/PBEF/ NAMPT circulatingconcentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutrition Metabolism and Cardiovascular Diseases Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, WagnerO, et al. The adipokine visfatin is markedly elevated in obese children. Journal of Pediatric Gastroenterology and Nutrition 2006; 43(4): Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H, et al. Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly 2009; 39(-2):22-7.